Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. - Wikidata - awgldk - TriplyDB

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

http://www.wikidata.org/entity/Q34785943

about

ROR1, an embryonic protein with an emerging role in cancer biology The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis Nanoscale monitoring of drug actions on cell membrane using atomic force microscopy The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction The pathogenesis of chronic lymphocytic leukemia Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.ROR1 expression correlated with poor clinical outcome in human ovarian cancer Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.Targeting malignant B cells with an immunotoxin against ROR1 ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.Antibody-based therapeutics for the treatment of human B cell malignancies Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.Expression of ROR1 in patients with renal cancer--a potential diagnostic marker.High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.Critical signal transduction pathways in CLL.

P2860

Q26828533-E5F92579-8FEE-4F40-9FEA-38EA8E52BEEA Q26829919-32E41F41-B298-4CE2-BA03-C91CC3005296 Q26852240-C0D9CB39-4404-4B08-B428-BEB21821014F Q26852972-2F42326F-2376-4DEE-B077-820A196F7D30 Q27025715-B4DED03D-1DB7-4453-A594-F109466F5D48 Q28478591-51F4C6B1-1087-422E-81D8-488BBC0CB57C Q28547292-131EAAE4-7955-49F5-8663-2B640985F5EE Q30008736-A8D1EA76-2769-4ADB-A82C-18044004AFFE Q33649606-A3AEC49C-F375-4DCB-AC9E-5D5279758C7A Q33779292-4219893A-E78F-4EF2-80D7-8C6B9FDCF422 Q33884816-28C116E9-71B6-4CE0-8947-6A60AAC7A47F Q33942010-C4AFB8EE-7DDC-4F55-95EA-868F41C0D4D6 Q34081881-F0C851C8-D376-4E9F-BE2D-B785D5CE89A8 Q34158454-7F4CEC3F-8D3B-422B-8702-59EA18967722 Q34189274-4ED7C3B7-458F-47A9-8196-D69987A5C2E6 Q34219505-9D8F5A35-FC40-43ED-BE1D-80B1427C5826 Q34374056-BCBF1BCA-7968-487F-96AE-AD89E942F351 Q34534333-C5B3BE9F-2030-4F69-9CCD-0B980E13E538 Q34674715-0B0FF846-7236-4CA2-9A8F-1F763177B52D Q34747359-2D5C56F5-0E4F-417B-8D24-8611C9795422 Q34797406-B091C3F1-10F5-4DF0-86C4-7CCEA2C45587 Q35029969-2EB0DC30-E961-4E35-B8A0-5BFED8F5A002 Q35036351-7593D410-052A-4F30-9BDA-1ADF1B5277E2 Q35200573-DB9358AE-3865-46B3-962E-E2C6552631C7 Q35648352-0F41DCEE-1821-42D7-92E1-13EE6B7959EE Q35839793-3E4D9A16-73A2-4F60-B825-47E3D099D024 Q35969887-85FAD0C6-C450-4A66-A729-EA808AEDD986 Q35971763-68F5D107-0C67-4328-A485-46AE6A5D9950 Q36194681-88F63FC0-39DA-4068-A6A4-60C7C20C9258 Q36294199-B5CB6625-A99B-41B5-B1A2-D109599EC0F5 Q36433018-5EAFD390-AD85-47DA-9D81-DF1E33783C76 Q36471596-4DC8EE60-2B05-4BC1-9089-053829CAE9F7 Q36515159-4B0DC5CE-3AD3-4FEA-A5D1-A50D93C6796B Q36907540-EC04BCDB-FF54-43B9-859C-72B96194DAD5 Q37244349-53BE3A62-EA62-44A0-BA3A-BFEE522541FF Q37320359-AD2C3E31-98BB-43A7-84EA-5C434D316405 Q37495234-675F424B-DC60-4461-AEBE-934F3414ECD4 Q37522298-34645D37-5946-45DE-9814-FB6E941EEF42 Q37528063-5F295223-C1B1-456B-AC27-8DB16DB8CD21 Q37571068-71CA754E-94F0-46C9-B438-A5E374F72133

P2860

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

http://www.wikidata.org/entity/Q34785943

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Ror1, a cell surface receptor ...... a putative target for therapy.

@ast

Ror1, a cell surface receptor ...... a putative target for therapy.

@en

Ror1, a cell surface receptor ...... a putative target for therapy.

@nl

type

label

Ror1, a cell surface receptor ...... a putative target for therapy.

@ast

Ror1, a cell surface receptor ...... a putative target for therapy.

@en

Ror1, a cell surface receptor ...... a putative target for therapy.

@nl

prefLabel

Ror1, a cell surface receptor ...... a putative target for therapy.

@ast

Ror1, a cell surface receptor ...... a putative target for therapy.

@en

Ror1, a cell surface receptor ...... a putative target for therapy.

@nl

P1433

Q34785943-C7251BCA-F63D-4569-89B1-1ABA22CE719B

P1476

Q34785943-D082DA24-AA8F-4D95-9A04-C3C8F6D8E1A4

P2093

Q34785943-125A0569-481D-417E-8487-B66344E16F3B

Q34785943-32A11BD5-7059-4B29-A3D5-445C87ACA786

Q34785943-466C0B95-82D4-4473-B0F7-AA528FCD3A50

Q34785943-4D449C77-456F-410C-9603-EAB724651DF5

Q34785943-5A691271-6A73-436B-86C8-199C7C2F5322

Q34785943-5C0AEC66-0E48-4A37-9DF6-9564BD6C817A

Q34785943-65658503-7635-4668-AE60-FB784A30AE04

Q34785943-65DAA74E-04ED-48FA-B309-C0B1FFAAE31C

Q34785943-7F4A9671-BCE2-4BE6-B26E-33EBAA126E71

Q34785943-91A83944-B99D-469C-B553-28F5B1C6DC37

P304

Q34785943-5F8D653B-D365-455F-AB69-D933D645D7D4

P31

Q34785943-3804E2C0-E3A1-4CC0-B649-56C5EC8C2603

P356

Q34785943-D85F245B-B247-48B1-A769-97AFB8E8E36F

P433

Q34785943-9A0060E8-6B31-418B-BDBC-085720B5AE20

P478

Q34785943-D862A35F-3FA1-4FCB-8969-9A4A26AAAF81

P577

Q34785943-8817522D-16BE-4701-94B1-B36FD479FFCB

P5875

Q34785943-1A92E456-27EB-47A0-ADA8-AE7BB8B56957

P698

Q34785943-1186C254-88FD-4B75-9237-21D2F5B5166C

P921

Q34785943-302F524D-42B1-412C-999E-C3C409EC5493

Q34785943-88374032-CAF4-4E77-994D-A1E914D5CB02

P356

P1433

International Journal of Cancer

P1476

Ror1, a cell surface receptor ...... a putative target for therapy.

@en

P2093

Ali Ahmad Bayat

http://www.w3.org/2001/XMLSchema#string

Amir H Daneshmanesh

http://www.w3.org/2001/XMLSchema#string

Anders Osterborg

http://www.w3.org/2001/XMLSchema#string

Catharina Larsson

http://www.w3.org/2001/XMLSchema#string

Eva Mikaelsson

http://www.w3.org/2001/XMLSchema#string

Fazel Shokri

http://www.w3.org/2001/XMLSchema#string

Hodjattallah Rabbani

http://www.w3.org/2001/XMLSchema#string

Håkan Mellstedt

http://www.w3.org/2001/XMLSchema#string

Mahmood Jeddi-Tehrani

http://www.w3.org/2001/XMLSchema#string

Mahyar Ostadkarampour

http://www.w3.org/2001/XMLSchema#string

P304

1190-1195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.23587

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5309522

http://www.w3.org/2001/XMLSchema#string

P698

18546292

http://www.w3.org/2001/XMLSchema#string

P921